https://www.dailysignal.com/2020/04/28/to-prepare-for-covid-19-vaccine-lets-ensure-manufacturing-capacity-will-meet-demand/?utm_source=rss&utm_medium=rss&utm_campaign=to-prepare-for-covid-19-vaccine-lets-ensure-manufacturing-capacity-will-meet-demand?utm_source=TDS_Email&utm_medium=email&utm_campaign=MorningBell&mkt_tok=eyJpIjoiWXprd1l6azRaalV5T1RSayIsInQiOiJMUitrRE9ySFlCczlwQlcra0pERXd5WE9NNTU5aEJcL0llbWVmQUhvU2dMSnpVVEF6dWg5R0ppZVZBaG82aHpkZG5FWkdqY1Ntc1BnR29kRkhGdkMxbmY5emJLZDllY1l5dFZJMXVcL0VnU2xRZ2ZHU3pTSTdFSmJaNmRLVlVsRlwvWSJ9
Pharmaceutical and biotech companies, in collaboration with scientists in academia and government, are working flat-out to develop drugs and vaccines to treat or prevent COVID-19.
Although a vaccine is still months away, policymakers and the public should ask now: If and when their efforts succeed, will there be sufficient manufacturing capacity to meet the likely enormous demand?
Fortunately, thanks to legislation passed by Congress back in 2004, President Donald Trump and his administration already have the authority they need to support and incentivize private companies with the relevant expertise and skills to build out manufacturing capacity as quickly as humanly possible.
Private industry faces significant risks in building manufacturing capacity at this stage. Given the national interest in making a vaccine available, the president should task his administration with acting now to prepare this capacity.
In these trying times, we must turn to the greatest document in the history of the world to promise freedom and opportunity to its citizens for guidance. Find out more now >>
How It Works
The Project BioShield Act of 2004 gave the Department of Homeland Security authority to determine if a chemical, biological, or radiological agent presents “a material threat against the United States population sufficient to affect national security.”